In the case of SS, since GLI and SMO were found to be overexpressed in patient’s tumors [198] and since Notch has been shown to activate GLI1, a Notch inhibitor in combination with vismodegib was tested in phase II trial that accepted SS patients to be enrolled (NCT01154452). Here, SMO is linked to synovial sarcoma.